<code id='2F54D1AF54'></code><style id='2F54D1AF54'></style>
    • <acronym id='2F54D1AF54'></acronym>
      <center id='2F54D1AF54'><center id='2F54D1AF54'><tfoot id='2F54D1AF54'></tfoot></center><abbr id='2F54D1AF54'><dir id='2F54D1AF54'><tfoot id='2F54D1AF54'></tfoot><noframes id='2F54D1AF54'>

    • <optgroup id='2F54D1AF54'><strike id='2F54D1AF54'><sup id='2F54D1AF54'></sup></strike><code id='2F54D1AF54'></code></optgroup>
        1. <b id='2F54D1AF54'><label id='2F54D1AF54'><select id='2F54D1AF54'><dt id='2F54D1AF54'><span id='2F54D1AF54'></span></dt></select></label></b><u id='2F54D1AF54'></u>
          <i id='2F54D1AF54'><strike id='2F54D1AF54'><tt id='2F54D1AF54'><pre id='2F54D1AF54'></pre></tt></strike></i>

          Home / knowledge / leisure time

          leisure time


          leisure time

          author:leisure time    Page View:182
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In